June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361–5.

Article  PubMed  CAS  Google Scholar 

Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. Anti-BCMA CAR T-Cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380(18):1726–37.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, et al. Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory multiple myeloma: CARTITUDE-1 2-Year Follow-Up. J Clin Oncol. 2023;41(6):1265–74.

Article  PubMed  CAS  Google Scholar 

Mullard A. FDA approves first BCMA-targeted CAR-T cell therapy. Nat Rev Drug Discov. 2021;20(5):332.

PubMed  Google Scholar 

Mullard A. FDA approves first CAR T therapy. Nat Rev Drug Discov. 2017;16(10):669.

PubMed  Google Scholar 

Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene Vicleucel in Relapsed and Refractory multiple myeloma. N Engl J Med. 2021;384(8):705–16.

Article  PubMed  CAS  Google Scholar 

Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-Cell therapy in relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med. 2020;382(14):1331–42.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma. N Engl J Med. 2019;380(1):45–56.

Article  PubMed  CAS  Google Scholar 

Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev. 2019;34:45–55.

Article  PubMed  CAS  Google Scholar 

Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and neurologic toxicity Associated with Immune Effector cells. Biol Blood Marrow Transpl. 2019;25(4):625–38.

Article  CAS  Google Scholar 

Faramand RG, Davila ML. CAR T-cell hematotoxicity: is inflammation the key? Blood. 2021;138(24):2447–8.

Article  PubMed  CAS  Google Scholar 

Freyer CW, Porter DL. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies. J Allergy Clin Immunol. 2020;146(5):940–8.

Article  PubMed  CAS  Google Scholar 

Yáñez L, Alarcón A, Sánchez-Escamilla M, Perales M-A. How I treat adverse effects of CAR-T cell therapy. ESMO Open. 2020;4(Suppl 4):e000746.

Article  PubMed  PubMed Central  Google Scholar 

Faramand R, Jain M, Staedtke V, Kotani H, Bai R, Reid K, et al. Tumor Microenvironment composition and severe cytokine release syndrome (CRS) influence toxicity in patients with large B-Cell lymphoma treated with Axicabtagene Ciloleucel. Clin Cancer Res. 2020;26(18):4823–31.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Fried S, Avigdor A, Bielorai B, Meir A, Besser MJ, Schachter J, et al. Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transpl. 2019;54(10):1643–50.

Article  CAS  Google Scholar 

Jain T, Knezevic A, Pennisi M, Chen Y, Ruiz JD, Purdon TJ, et al. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Adv. 2020;4(15):3776–87.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Li H, Zhao L, Sun Z, Yao Y, Li L, Wang J, et al. Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma. Front Immunol. 2022;13:1019548.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Qualls D, Jacobson C. A road map for navigating CAR T hematotoxicity. Blood. 2023;142(10):859–61.

Article  PubMed  CAS  Google Scholar 

Rejeski K, Subklewe M, Aljurf M, Bachy E, Balduzzi A, Barba P, et al. Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations. Blood. 2023;142(10):865–77.

Article  PubMed  CAS  Google Scholar 

Rejeski K, Perez A, Sesques P, Hoster E, Berger C, Jentzsch L, et al. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma. Blood. 2021;138(24):2499–513.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Si X, Gu T, Liu L, Huang Y, Han Y, Qian P, et al. Hematologic cytopenia post CAR T cell therapy: etiology, potential mechanisms and perspective. Cancer Lett. 2022;550:215920.

Article  PubMed  CAS  Google Scholar 

Rejeski K, Perez A, Iacoboni G, Penack O, Bücklein V, Jentzsch L et al. The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL. J Immunother Cancer. 2022;10(5).

Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory large B-Cell lymphoma. N Engl J Med. 2017;377(26):2531–44.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 2019;20(1):31–42.

Article  PubMed  CAS  Google Scholar 

Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22(10):1403–15.

Article  PubMed  CAS  Google Scholar 

Wang L, Hong R, Zhou L, Wang Y, Lv Y, Ni F, et al. Cytokine profiles are associated with prolonged hematologic toxicities after B-cell maturation antigen targeted chimeric antigen receptor-T-cell therapy. Cytotherapy. 2023;25(2):192–201.

Article  PubMed  Google Scholar 

Jess J, Yates B, Dulau-Florea A, Parker K, Inglefield J, Lichtenstein D et al. CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicity. J Immunother Cancer. 2023;11(6).

Shouse G, Cao T, Zhang J, Mei M, Herrera AF, Nikolaenko L, et al. Incidence and causes of prolonged hematologic toxicity after Chimeric Antigen Receptor T cell therapy: a City of Hope (COH) experience. Blood. 2020;136:40–1.

Article  Google Scholar 

Nagle SJ, Murphree C, Raess PW, Schachter L, Chen A, Hayes-Lattin B, et al. Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies. Am J Hematol. 2021;96(4):455–61.

Article  PubMed  CAS  Google Scholar 

Taneja A, Jain T, CAR-T-OPENIA. Chimeric antigen receptor T-cell therapy-associated cytopenias. EJHaem. 2022;3(Suppl 1):32–8.

Article  PubMed  Google Scholar 

Li X, Deng Q, Henderson J, Watson G, Deaton L, Cain T, et al. Targetable cellular etiology of prolonged cytopenia following CD19 CAR T-cell therapy. Blood. 2022;140(Supplement 1):4502–3.

Article  Google Scholar 

Jain T, Olson TS, Locke FL. How I treat cytopenias after CAR T-cell therapy. Blood J Am Soc Hematol. 2023;141(20):2460–9.

CAS  Google Scholar 

Strati P, Varma A, Adkins S, Nastoupil LJ, Westin J, Hagemeister FB, et al. Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma. Haematologica. 2021;106(10):2667–72.

Article  PubMed  CAS  Google Scholar